尔康制药(300267.SZ)：控股股东拟减持不超过2.04%股份

Core Viewpoint - The controlling shareholder of Erkang Pharmaceutical, Mr. Shuai Fangwen, plans to reduce his shareholding by up to 42 million shares, representing 2.04% of the company's total equity, within a specified timeframe [1] Shareholding Details - Mr. Shuai Fangwen currently holds 853,574,906 shares, which accounts for 41.38% of the total share capital of the company [1] - The planned reduction will take place from October 29, 2025, to January 28, 2026, through centralized bidding or block trading [1]